Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $9.2B? Odds fell to 0% on Jul 15, 2026

ResolvedOutcome: NoMove

Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $9.2B? On , the market’s odds fell from 17¢ to 0.1¢ (-16.9 pts) within an hour of an AI-matched news signal from livesquawk. The market has since resolved No.

How did the odds move?

At match17¢
+5m17¢
+30m0.1¢
+1h0.1¢
1h move-16.9 pts

Yes-side prices at the moment the news was matched and at the stamped impact windows after it. Windows the tracker could not measure inside its honesty band are omitted, never estimated.

What moved the odds?

Nolivesquawk99%match
$JNJ Johnson & Johnson Q2 2026 Earnings • -Adj EPS $2.90 (est $2.85) • -Sales $25.31B (est 25.04B) • -Medtech Sales $8.93b (est $8.99b) • -Medicine Revenue $16.38b (est $16.12b) • -Sees FY Sales $100.88 To $101.48, Saw $100.3b To $101.3b • -Sees FY Adj EPS $11.60 To $11.75, Saw $11.45 To $11.65 • Sees FY Sales $100.8b To $101.4b, Saw $100.3b To $101.3b

Where does this market stand now?

This market has resolved No. Final market pricing put YES at 0%, as of .

YES0¢
NO100¢

Vol$2K

Follow this market

Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above $9.2B? — live odds, order flow, and the full signal timeline.

See all outcomes for Will Johnson & Johnson (JNJ) Q2 MedTech revenue be above __? — the full event, with combined odds and signal timeline.